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Abstract
Introduction: Sample type recommended by the manufacturer for the digoxin Abbott assay is either serum collected in glass tubes or plasma 
(sodium heparin, lithium heparin, citrate, EDTA or oxalate as anticoagulant) collected in plastic tubes. In our hospital samples are collected in plastic 
tubes. Our hypothesis was that the serum sample collected in plastic serum tube can be used interchangeably with plasma sample for measurement 
of digoxin concentration. Our aim was verification of plastic serum tubes for determination of digoxin concentration.
Materials and methods: Concentration of digoxin was determined simultaneously in 26 venous blood plasma (plastic Vacuette, LH Lithium hepa-
rin) and serum (plastic Vacuette, Z Serum Clot activator; both Greiner Bio-One GmbH, Kremsmünster, Austria) samples, on Abbott AxSYM analyzer 
using the original Abbott Digoxin III assay (Abbott, Wiesbaden, Germany). Tube comparability was assessed using the Passing Bablok regression and 
Bland-Altman plot.
Results: Serum and plasma digoxin concentrations are comparable. Passing Bablok intercept (0.08 [95% CI = -0.10 to 0.20]) and slope (0.99 [95% CI 
= 0.92 to 1.11]) showed there is no constant or proportional error.
Conclusion: Blood samples drawn in plastic serum tubes and plastic plasma tubes can be interchangeably used for determination of digoxin con-
centration.
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Digoxin is one of the most prescribed drugs in 
treatment of patients with diagnosis of cardiac 
heart failure and certain types of cardiac arrhyth-
mias. It has narrow therapeutic range and its de-
termination represents valuable tool for efficient 
management of patients (1). Reliable information 
on digoxin concentration is necessary for patients 
from the emergency department suspected for 
taking toxic concentration of digoxin or patients 
who need dosage adjustment (2).
Selection of plasma as sample type has advantag-
es and disadvantages when therapeutic drug 
monitoring is concerned. Advantages of plasma in 
relation to serum are reduced risk of haemolysis 
and sample volume and disadvantage is related to 
dilution and interfering effect of anticoagulant (3). 
Manufacturers of the test kits for therapeutic drug 
monitoring usually recommend various sample 
types dependent of the drug tested, leaving the 
decision on the most suitable sample in particular 
setting to the laboratory manager. Serum test 
tubes containing separator gel generally should 
be avoided in therapeutic drug monitoring be-
cause of its influence on the tested drug (4). Only 
25% of the digoxin concentration is protein-bound. 
Measurement of fraction of free digoxin concen-
tration is needed when immunoreactive digoxin-
like substances are present or digoxin-intoxicated 
patients are treated with digibind (5).
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Automated processing of the patient samples en-
sures reliable results. Nevertheless, preanalytical 
phase of the total processing of the sample is still 
weak point (6). Many efforts are taken for improve-
ment and quality assurance from the number of 
industrial representatives, as well as international 
expert working groups (7).
In last two decades, blood collection device man-
ufacturers switched from glass to plastic tube pro-
duction (8,9). In the package insert for the reagent 
for determination of digoxin concentration (Dig-
oxin III, Ref. 6L07, Abbott, Wiesbaden, Germany) 
manufacturer recommends serum collected in 
glass serum tubes or plasma (sodium heparin, lith-
ium heparin, citrate, EDTA or oxalate) collected in 
plastic tubes as sample type convenient for digox-
in assay. In our daily practice we use plastic tubes. 
We wanted to investigate the comparability of dig-
oxin concentration in plastic serum and heparinized 
plasma tubes respecting the guidelines for tube 
verification (10).
Our hypothesis was that the serum sample collect-
ed in plastic serum tube can be used interchange-
ably with plasma sample for measurement of dig-
oxin concentration. Our aim was verification of 




Specimen collection was performed on hospital 
wards of Medical School University Hospital Sestre 
Milosrdnice in the period from 18th April to 4th 
June of 2013. Only patients for whom digoxin anal-
ysis was routinely requested on that day were re-
cruited into study. Venous plasma and serum sam-
ples from plastic tubes drawn from 28 patients 
were analysed for concentration of digoxin. For 
two patients concentrations of digoxin were ex-
cluded from data analysis, one because of results 
below the lower limit of the measurement range, 
and other because of the specific error code which 
demands additional pre-treatment of the sample. 
Occasionally specific error codes occur during 
analysis, for which manufacturer recommends us-
ing one or both pre-treatment procedures for the 
sample. These pre-treatments are manual dilution 
of the sample with original Calibrator A (digoxin = 
0 nmol/L) and centrifuging of the specimen. After 
recommended procedure is performed, result 
within measurement range is obtained. Out of the 
total number of patients included in the study (N = 
26), thirteen patients were from Emergency de-
partment, nine from Cardiology department, two 
were outpatients from University Department of 
Chemistry and single samples were obtained from 
Hemato-oncological and Pulmology department, 
respectively. Blood sampling was done in the 
morning. For patients from the hospital wards, 
timing of sampling was defined by physician and 
for laboratory outpatients sampling was per-
formed after fasting in the period of 7.30-9.00 a.m.
For each patient one additional tube was drawn. 
Venous blood samples were taken to serum (Vacu-
ette® Z Serum Clot Activator, 4 mL, Ref. 454204, 
Greiner Bio-One GmbH, Kremsmünster, Austria) 
and then to plasma plastic tubes (Vacuette® LH 
Lithium Heparin, 4,5 mL Ref. 454049, Greiner Bio-
One GmbH, Kremsmünster, Austria) in a single 
venipuncture respecting the order of blood draw 
(11). The study complies with the ethical principles 
of the Declaration of Helsinki.
Methods
After collection, tubes were transported to bio-
chemistry laboratory of the University Department 
of Chemistry. Samples were centrifuged on a 
benchtop centrifuge for 10 minutes at 1800 x g; 
plasma samples immediately upon delivery and 
serum samples after 30 minutes in upright posi-
tion. Concentration of digoxin was measured on 
the AxSYM analyzer (Abbott Laboratories, Abbott 
Park, IL, USA) using the Digoxin III Reagent pack 
(Ref. 6L07, rev. September 2010, Abbott, Wies-
baden, Germany). AxSYM Digoxin III assay uses mi-
croparticle enzyme immunoassay (MEIA) principle 
for measurement of digoxin concentration. Patient 
sample is mixed with anti-digoxin coated micro-
particles and digoxin-alkaline phosphatase conju-
gate. Digoxin from the sample competes with dig-
oxin-alkaline phosphatase conjugate for binding 
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with the anti-digoxin coated microparticles to 
form antibody-antigen complexes and antibody-
conjugate complexes. After addition of the sub-
strate, fluorescent product is measured. Measure-
ment range for the assay is from 0.4 to 5.1 nmol/L. 
Daily quality control for digoxin was performed 
with commercial control package Digoxin III Con-
trols (Ref. 6L07-10, Abbott, Wiesbaden, Germany).
Statistical analysis
Data were presented as median and interquartile 
range. Wilcoxon test for paired samples non-nor-
mally distributed was used for assessment of sig-
nificance of difference between data sets. Mean 
bias between serum and plasma tubes were calcu-
lated and compared with the acceptable % root 
mean standard deviation according to RiliBÄK of 
14% (12). Passing and Bablok regression analysis 
and Bland-Altman plot were performed according 
to the guidelines (10,13). On the horizontal axis 
were results of the digoxin concentration from 
plasma tube and on the vertical axis were results 
from serum tube. Proportional and constant errors 
were assessed by means of Passing and Bablok re-
gression equation and relation of mean values to 
the difference between measurements by the 
Bland-Altman plot. For data analysis MedCalc sta-
tistical software version 12.1.4.0 (MedCalc soft-
ware, Mariakerke, Belgium) was used. P-value < 
0.05 was considered statistically significant.
Results
In total, twenty-six paired patient data were ana-
lysed. Median digoxin concentrations and respec-
tive mean bias are shown in Table 1. The mean bias 
did not exceed the method quality specifications 
for total allowable error. Wilcoxon test for paired 
samples was used for data analysis and result for 
significance level was P = 0.025. Although statisti-
cal difference was found, mean bias was within 
limits for acceptable % root mean standard devia-
tion according to RiliBÄK.
Lowest concentration of digoxin concentration 
obtained was 0.62 nmol/L, and the highest value 
was 4.44 nmol/L, covering the assay measurement 
range. Data analysis using Passing and Bablok re-
gression (Figure 1) showed the absence of bias and 
proportional differences. Intercept and slope were 
0.08 (95% CI = -0,10 to 0.20) and 0.99 (95% CI = 0.92 
to 1.11), respectively. Bland-Altman plot (Figure 2) 
did not show significant differences in data sets.
Discussion
Our study showed that digoxin concentration re-
sults obtained from venous plasma or serum plas-
tic tubes can be used interchangeably. In manu-
facturers declaration regarding sample type there 
is recommendation to use only serum glass tubes. 
It would be more convenient to evaluate plastic 
serum tube vs. glass serum tube taking the glass 
tube as reference. As we use plastic tubes almost 
exclusively, we decided to take plasma plastic tube 
as the reference tube.
Preanalytical phase makes the most vulnerable 
part of the total testing process (7). There is a vast 
number of factors affecting correct and reliable 
process of patient identification, blood sampling 
and preparation for analysis. One of them is for 
sure specimen collection tube. There is a vast 
number of venous blood tubes available in the 
market. In order to secure reliability of test results, 
CLSI established protocol for tube validation for 
manufacturers similar to the protocols used for as-
say validation (11).
Serum Plasma Mean bias (%) Total allowable error (%) P
Digoxin concentration 
(nmol/L) 1.88 (1.14-2.57) 1.82 (1.08-2.42) 8.1 14 0.025
Data are presented as median and interquartile range.
Table 1. Calculated bias for digoxin concentrations measured in serum and plasma.
http://dx.doi.org/10.11613/BM.2014.016 Biochemia Medica 2014;24(1):146–50 
  149
Dukić L. et al. Comparison of digoxin in plasma and serum
Plastic blood collection tubes are more resistant to 
breakage which makes them safer for handling in 
relation to glass tubes. Their weight is smaller and 
they are more convenient for disposal. On the oth-
er hand, glass tubes are more resistant to penetra-
tion of water or air into the collecting system and 
less susceptible on temperature changes (8,9,14). 
Most of the plastic tubes are produced from poly-
propylene (PP) and polyethylene terephtalate 
(PET) (15). In our study, PET tubes were used. They 
are generally considered more reliable regarding 
declared shelf life because of their ability to main-
tain vacuum. Their disadvantage in relation to PP 
tubes is inability to maintain proper concentration 
of anticoagulant because of liquid evaporation.
Routine clinical chemistry parameter results from 
different blood collection tubes were compared 
finding no significant differences for the most of 
the routine parameters (16). However, authors em-
phasized the importance of tube validation for 
prevention of possible errors in laboratory testing. 
Another study focused on routine hematology pa-
rameters and tested performance characteristics 
of different hematology tubes from various manu-
facturers. Testing was performed in specialized 
laboratory before their intended use and author 
found remarkable variations in quality of anticoag-
ulants used and declared shelf-life (17). In the com-
parison study of glass and plastic tubes for digoxin 
concentration testing which included also study 
on storage effect no significant differences were 
found (18). We did not evaluate effect of storage in 
plasma or serum tubes for digoxin concentration.
Further efforts are needed in order to improve 
quality of all in-vitro devices and more strict regu-
lations for manufacturers and end-users in order 
to avoid errors caused by inappropriate blood con-
tainers.
Limitations of our study are lack of glass tube as 
reference material and small number of samples 
included in validation protocol. It would be also in-
teresting to check effect of storage in plasma and 
serum plastic tubes. Nevertheless, we managed to 
check the reliability of the testing in different ma-
trix by simple method. For quality improvement it 
is necessary to record all the changes in testing 
process and evaluate their impact on patient re-
sults using the defined guidelines.
In conclusion, plasma heparin tubes and plastic se-
rum tubes can be used interchangeably for moni-
toring of digoxin concentration.
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Figure 1. Passing and Bablok regression.
Solid line represents regression line; dashed lines represent CI 
for the regression line; dotted line is identity line (x = y). y = 0.08 
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Figure 2. Bland-Altman plot represents scatter diagram of the 
differences between plasma and serum digoxin concentration 
in relation to their mean values.
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